A Prospective Observational Study of Erivedge Treatment, Effectiveness, and Safety Outcomes in Patients With Advanced Basal Cell Carcinoma

Trial Profile

A Prospective Observational Study of Erivedge Treatment, Effectiveness, and Safety Outcomes in Patients With Advanced Basal Cell Carcinoma

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Aug 2018

At a glance

  • Drugs Vismodegib (Primary)
  • Indications Basal cell cancer; Basal cell nevus syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ROSETT
  • Sponsors Roche
  • Most Recent Events

    • 24 Jul 2018 Planned End Date changed from 19 Dec 2020 to 29 Aug 2020.
    • 24 Jul 2018 Planned primary completion date changed from 19 Dec 2020 to 29 Aug 2020.
    • 17 Nov 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top